Oncology · Immune Checkpoint InhibitorRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for YERVOY (ipilimumab) by Bristol Myers Squibb

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:31:53 PM

Assessment confidence: 90% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for YERVOY represents a significant regulatory milestone for Bristol Myers Squibb, potentially enhancing their competitive position in the oncology market. This development warrants close monitoring as it may influence future market dynamics and strategic decisions. Regulatory context from FDA (FDA AP — YERVOY (SUPPL)) supports the near-term read. Assessment grounded in 31 ranked evidence items (31 high-relevance).

Strategic Assessment

Strategic focus on the development and marketing of YERVOY could strengthen Bristol Myers Squibb's oncology portfolio. The strongest clinical anchor is Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors (ClinicalTrials.gov), mechanism alignment (checkpoint); sponsor/company relevance (bristol myers squibb). In Oncology · Immune Checkpoint Inhibitor, 8 regulatory and 7 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert (Bristol Myers Squibb) — entity match (bristol myers squibb).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — YERVOY (SUPPL) (FDA). Entity match (bristol myers squibb). The acceptance of the supplemental application indicates a favorable regulatory environment, but the final approval will be critical for compliance and market access.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the supplemental application could lead to increased market share for YERVOY, impacting revenue positively for Bristol Myers Squibb in the oncology sector.
Upside for Bristol Myers Squibb may improve if Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota. (PubMed) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the supplemental application and any subsequent FDA decisions or updates.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — OPDUALAG (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — OPDIVO (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Investigational New Drug (IND) Application
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
FDA AP — OPDIVO QVANTIG (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
ClinicalTrials.govhigh relevance
Mechanism alignment (CHECKPOINT); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Cohort Study on Neuroimmune Diseases in the Reproductive Age
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
FDA Grants Priority Review for Welireg Supplement NDA215383
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer
Humanexa Signalshigh relevance
Entity match (oncology)

Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota.
PubMedhigh relevance
Mechanism alignment (CHECKPOINT); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Epstein-Barr virus reprograms immune escape in nasopharyngeal carcinoma.
PubMedhigh relevance
Mechanism alignment (CHECKPOINT); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Comparison of Transumbilical Single‑Port and Multi‑Port Laparoscopic Myomectomy in Patients with Uterine Fibroids: Effects on Stress Response, Immune Function, and Incision Cosmetic Outcomes.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
YERVOY
Oncology

Commercial impact

medium

If approved, the supplemental application could lead to increased market share for YERVOY, impacting revenue positively for Bristol Myers Squibb in the oncology sector.

Regulatory impact

medium

The acceptance of the supplemental application indicates a favorable regulatory environment, but the final approval will be critical for compliance and market access.

What to watch

Monitor the progress of the supplemental application and any subsequent FDA decisions or updates.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.